Bridgewater Associates’s Exelixis EXEL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$21.8M Sell
400,859
-80,137
-17% -$3.9M 0.09% 189
2026
Q1
$20.6M Sell
480,996
-444,716
-48% -$19.1M 0.09% 153
2025
Q4
$40.6M Buy
925,712
+82,747
+10% +$3.42M 0.15% 112
2025
Q3
$34.8M Buy
842,965
+822,100
+3,940% +$33M 0.14% 123
2025
Q2
$920K Buy
20,865
+12,550
+151% +$502K ﹤0.01% 477
2025
Q1
$307K Buy
+8,315
New +$296K ﹤0.01% 607
2023
Q1
– Sell
-17,322
Closed -$278K – 784
2022
Q4
$278K Buy
+17,322
New +$282K ﹤0.01% 779
2022
Q3
– Sell
-21,808
Closed -$454K – 917
2022
Q2
$454K Buy
21,808
+4,961
+29% +$102K ﹤0.01% 902
2022
Q1
$382K Buy
+16,847
New +$329K ﹤0.01% 917
2021
Q3
– Sell
-16,821
Closed -$306K – 720
2021
Q2
$306K Buy
+16,821
New +$392K ﹤0.01% 681

Other funds holding EXEL

Bridgewater Associates's EXEL Position: Q2 2026 in Review

Bridgewater Associates reduced its Exelixis (EXEL) stake by 17% in Q2 2026, selling an estimated $3.9M and leaving 400,859 shares worth $21.8M. The position accounts for 0.09% of the portfolio, ranked #189.

Bridgewater Associates first reported a position in EXEL in Q2 2021 and has held it in 10 quarters since. The position peaked at $40.6M in Q4 2025. 760 funds tracked by Wall St. Rank hold EXEL as of Q2 2026.

  • Bridgewater Associates held 400,859 shares of Exelixis worth $21.8M as of Q2 2026.
  • Bridgewater Associates sold 80,137 Exelixis shares in Q2 2026, an estimated $3.9M.
  • Exelixis made up 0.09% of Bridgewater Associates's portfolio in Q2 2026, its #189 holding.
  • Bridgewater Associates first reported a position in Exelixis in Q2 2021 and has held it in 10 quarters since.
  • Bridgewater Associates's Exelixis position peaked at $40.6M in Q4 2025.
  • 760 funds tracked by Wall St. Rank held Exelixis as of Q2 2026.

Based on Bridgewater Associates's 13F filing for Q2 2026, filed 14 Aug 2026.